{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:12Z","timestamp":1787020332961,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z191100008319009"],"award-info":[{"award-number":["Z191100008319009"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many factors contribute to quality of life (QoL) in patients with schizophrenia, yet limited research examined these factors in patients in China. This cross-sectional study explores subjective QoL and its associated factors in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The QoL was assessed using the Schizophrenia Quality of Life Scale (SQLS). Clinical symptoms were evaluated using the Brief Psychiatric Rating Scale (BPRS) and seven factors were extracted. Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder Scale (GAD-7) were used to assess depression and anxiety. Cognitive impairment was assessed using the Ascertain Dementia 8 (AD8). The Treatment Emergent Symptom Scale (TESS) and Rating Scale for Extrapyramidal Side Effects (RSESE) were used to evaluate the side effects of medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We recruited 270 patients (male:142,52.6%, mean age:41.9\u2009\u00b1\u20099.4\u00a0years). Positive correlations were observed between SQLS and its subdomains with the total score of BPRS, PHQ-9, GAD-7, AD8, TESS, and RSESE (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005). Patients who were taking activating second-generation antipsychotics (SGAs) had lower scores on total SQLS, Motivation\/ Energy domain of SQLS (SQLS-ME)\u00a0as well as Symptoms\/ Side effects domain of SQLS (SQLS-SS) compared to those taking non-activating SGAs (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005). Multiple regression analysis showed that depressive\/ anxiety symptoms and cognitive impairment had significant negative effects on QoL (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009\u2264\u20090.001), while activating SGAs had a positive effect (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.005). Blunted affect and unemployment were inversely associated with the motivation\/energy domain (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings emphasize the important role of depression\/anxiety symptoms and cognitive impairment in the QoL of patients with chronic schizophrenia. Activating SGAs and employment may improve the QoL of these individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This protocol was registered at chictr.org.cn (Identifier: ChiCTR2100043537).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-024-05929-3","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:02:30Z","timestamp":1719907350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in Chronic Schizophrenia"],"prefix":"10.1186","volume":"24","author":[{"given":"Dan-na","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-qing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-lang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"5929_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12888-021-03318-8","volume":"21","author":"U Stentzel","year":"2021","unstructured":"Stentzel U, Van Den Berg N, Moon K, Schulze LN, Schulte J, Langosch JM, et al. Telemedical care and quality of life in patients with schizophrenia and bipolar disorder: results of a randomized controlled trial. BMC Psychiatry. 2021;21(1):318.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"5929_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/08039488.2012.687768","volume":"67","author":"PK Chugh","year":"2013","unstructured":"Chugh PK, Rehan HS, Unni KES, Sah RK. Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry. 2013;67(3):153\u20138.","journal-title":"Nord J Psychiatry"},{"key":"5929_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2147\/NDT.S171207","volume":"14","author":"T Tominaga","year":"2018","unstructured":"Tominaga T, Tomotake M, Takeda T, Ueoka Y, Tanaka T, Watanabe S, ya, et al. Relationship between social and cognitive functions in people with schizophrenia. Neuropsych Dis Treat. 2018;14:2215\u201324.","journal-title":"Neuropsych Dis Treat"},{"issue":"5","key":"5929_CR4","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/schbul\/sbl071","volume":"33","author":"SM Eack","year":"2007","unstructured":"Eack SM, Newhill CE. Psychiatric symptoms and quality of life in Schizophrenia: a Meta-analysis. Schizophr Bull. 2007;33(5):1225\u201337.","journal-title":"Schizophr Bull"},{"issue":"1","key":"5929_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12888-023-05303-9","volume":"23","author":"Z Mao","year":"2023","unstructured":"Mao Z, Tian L, Sun Y, Dong F, Wang C, Bo Q. Quality of life and its predictors in first-episode schizophrenia and individuals at clinical high-risk for psychosis. BMC Psychiatry. 2023;23(1):793.","journal-title":"BMC Psychiatry"},{"issue":"12","key":"5929_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2152\/jmi.69.80","volume":"69","author":"Y Ishii","year":"2022","unstructured":"Ishii Y, Tomotake M, Chiba S, Tsutsumi R, Aono M, Taguchi K. Relationship between quality of life and clinical factors in inpatients with schizophrenia. J Med Investig. 2022;69(12):80\u20135.","journal-title":"J Med Investig"},{"issue":"3","key":"5929_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/1440-1630.12855","volume":"70","author":"S Ercan Do\u011fu","year":"2023","unstructured":"Ercan Do\u011fu S, \u00d6rsel S. The relationship between psychopathology, occupational balance, and quality of life among people with schizophrenia. Aust Occup Ther J. 2023;70(3):314\u201326.","journal-title":"Aust Occup Ther J"},{"issue":"3","key":"5929_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pnpbp.2010.01.014","volume":"34","author":"PS Woon","year":"2010","unstructured":"Woon PS, Chia MY, Chan WY, Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):463\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"5929_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1590\/1516-4446-2015-1776","volume":"38","author":"BF Cruz","year":"2016","unstructured":"Cruz BF, Resende CBD, Carvalhaes CF, Cardoso CS, Teixeira AL, Keefe RS, et al. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms. Rev Bras Psiquiatr. 2016;38(3):216\u201321.","journal-title":"Rev Bras Psiquiatr"},{"issue":"6","key":"5929_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s11136-007-9195-3","volume":"16","author":"MS Ritsner","year":"2007","unstructured":"Ritsner MS. Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Qual Life Res. 2007;16(6):929\u201337.","journal-title":"Qual Life Res"},{"issue":"8","key":"5929_CR11","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00127-020-01880-2","volume":"56","author":"N Hoertel","year":"2021","unstructured":"Hoertel N, Rotenberg L, Blanco C, Camus V, Dubertret C, Charlot V, et al. A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study. Soc Psychiatry Psychiatr Epidemiol. 2021;56(8):1411\u201325.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"6","key":"5929_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0278-5846(02)00217-8","volume":"26","author":"G Aksaray","year":"2002","unstructured":"Aksaray G, Oflu S, Kaptano\u01e7lu C, Bal C. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1217\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"5929_CR13","doi-asserted-by":"publisher","first-page":"e0229514","DOI":"10.1371\/journal.pone.0229514","volume":"15","author":"D Desalegn","year":"2020","unstructured":"Desalegn D, Girma S, Abdeta T. Quality of life and its association with psychiatric symptoms and socio-demographic characteristics among people with schizophrenia: a hospital-based cross-sectional study. PLoS ONE. 2020;15(2):e0229514.","journal-title":"PLoS ONE"},{"issue":"1","key":"5929_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","volume":"162","author":"A Karow","year":"2002","unstructured":"Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology. 2002;162(1):3\u201310.","journal-title":"Psychopharmacology"},{"issue":"1","key":"5929_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12991-020-00292-5","volume":"19","author":"R Tandon","year":"2020","unstructured":"Tandon R, Lenderking WR, Weiss C, Shalhoub H, Barbosa CD, Chen J, et al. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann Gen Psychiatry. 2020;19(1):42.","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"5929_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","volume":"15","author":"L Colonna","year":"2000","unstructured":"Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15(1):13\u201322.","journal-title":"Int Clin Psychopharmacol"},{"issue":"18","key":"5929_CR17","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.3390\/ijms231810624","volume":"23","author":"J Orzelska-G\u00f3rka","year":"2022","unstructured":"Orzelska-G\u00f3rka J, Mikulska J, Wiszniewska A, Bia\u0142a G. New atypical antipsychotics in the treatment of Schizophrenia and Depression. Int J Mol Sci. 2022;23(18):10624.","journal-title":"Int J Mol Sci"},{"key":"5929_CR18","doi-asserted-by":"publisher","first-page":"834333","DOI":"10.3389\/fpsyt.2022.834333","volume":"13","author":"M\u00d8 Nielsen","year":"2022","unstructured":"Nielsen M\u00d8, Kristensen TD, Borup Bojesen K, Glenth\u00f8j BY, Lemvigh CK, Ebdrup BH. Differential effects of Aripiprazole and Amisulpride on negative and cognitive symptoms in patients with First-Episode psychoses. Front Psychiatry. 2022;13:834333.","journal-title":"Front Psychiatry"},{"issue":"4","key":"5929_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1185\/03007990903576953","volume":"26","author":"P Nuss","year":"2010","unstructured":"Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010;26(4):787\u2013801.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"5929_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S1461145703003651","volume":"6","author":"S Kasper","year":"2003","unstructured":"Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325\u201337.","journal-title":"Int J Neuropsychopharmacol"},{"key":"5929_CR21","doi-asserted-by":"crossref","unstructured":"Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA et al. Symptom Dimension of Interest-Activity indicates need for Aripiprazole Augmentation of Escitalopram in Major Depressive disorder: a CAN-BIND-1 report. J Clin Psychiatry 2020; 81(4).","DOI":"10.4088\/JCP.20m13229"},{"issue":"4","key":"5929_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40263-021-00803-2","volume":"35","author":"E Morton","year":"2021","unstructured":"Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, McInerney S, et al. Predictors of quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in patients with major depressive disorder: a CAN-BIND Study Report. CNS Drugs. 2021;35(4):439\u201350.","journal-title":"CNS Drugs"},{"issue":"8","key":"5929_CR23","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s11136-020-02470-0","volume":"29","author":"A Bergh\u00f6fer","year":"2020","unstructured":"Bergh\u00f6fer A, Martin L, Hense S, Weinmann S, Roll S. Quality of life in patients with severe mental illness: a cross-sectional survey in an integrated outpatient health care model. Qual Life Res. 2020;29(8):2073\u201387.","journal-title":"Qual Life Res"},{"issue":"5","key":"5929_CR24","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41380-023-02003-4","volume":"28","author":"G Fond","year":"2023","unstructured":"Fond G, Vidal M, Joseph M, Etchecopar-Etchart D, Solmi M, Yon DK, et al. Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries. Mol Psychiatry. 2023;28(5):1920\u201331.","journal-title":"Mol Psychiatry"},{"key":"5929_CR25","volume-title":"Diagnostic and Statistical Manual for Mental Disorders. Forth Edition, text revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Forth Edition, text revision. Washington, DC: American Psychiatric Association; 2000. [M]."},{"issue":"suppl 1","key":"5929_CR26","first-page":"S90","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD Method. Schizophr. Bull. 2016;42(suppl 1):S90\u20134.","journal-title":"Bull"},{"issue":"1","key":"5929_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.177.1.42","volume":"177","author":"G Wilkinson","year":"2000","unstructured":"Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177(1):42\u20136.","journal-title":"Br J Psychiatry"},{"key":"5929_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"issue":"3","key":"5929_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in Schizophrenia: proposed Criteria and Rationale for Consensus. Am J Psychiatry. 2005;162(3):441\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5929_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.rcp.2019.09.001","volume":"50","author":"CA Cassiani-Miranda","year":"2021","unstructured":"Cassiani-Miranda CA, Cuadros-Cruz AK, Torres-Pinz\u00f3n H, Scoppetta O, Pinz\u00f3n-Tarrazona JH, L\u00f3pez-Fuentes WY, et al. Validez Del Cuestionario De salud del paciente-9 (PHQ-9) para cribado de depresi\u00f3n en adultos usuarios de Atenci\u00f3n primaria en Bucaramanga, Colombia. Rev Colomb Psiquiatr. 2021;50(1):11\u201321.","journal-title":"Rev Colomb Psiquiatr"},{"issue":"10","key":"5929_CR31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092.","journal-title":"Arch Intern Med"},{"issue":"4","key":"5929_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000172958.95282.2a","volume":"65","author":"JE Galvin","year":"2005","unstructured":"Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559\u201364.","journal-title":"Neurology"},{"issue":"5","key":"5929_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/archneur.64.5.725","volume":"64","author":"JE Galvin","year":"2007","unstructured":"Galvin JE, Roe CM, Coats MA, Morris JC. Patient\u2019s rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating Tool to detect dementia. Arch Neurol. 2007;64(5):725.","journal-title":"Arch Neurol"},{"issue":"3","key":"5929_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/fampra\/cmx098","volume":"35","author":"HH Chen","year":"2018","unstructured":"Chen HH, Sun FJ, Yeh TL, Liu HE, Huang HL, Kuo BIT, et al. The diagnostic accuracy of the Ascertain Dementia 8 questionnaire for detecting cognitive impairment in primary care in the community, clinics and hospitals: a systematic review and meta-analysis. Fam Pract. 2018;35(3):239\u201346.","journal-title":"Fam Pract"},{"key":"5929_CR35","unstructured":"National Institute of Mental Health. TESS (Treatment Emergent Symptom Scale-write-in.) Psychopharmacol Bull [M]. 1985; 1069\u201372."},{"issue":"S212","key":"5929_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"45","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Gh BMB, Angus JWS, FRC P. M. DP. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS. Acta Psychiatr Scand. 1970;45(S212):11\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"5929_CR37","doi-asserted-by":"crossref","unstructured":"Chen Zhua, Wang G hua, Wang X, ping, Chen R, yun, Wang H, lin, Yang M et al. hua,. Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr. Ther. Res. 2008; 69(2): 104\u2013117.","DOI":"10.1016\/j.curtheres.2008.04.008"},{"issue":"2","key":"5929_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0447.1998.tb10053.x","volume":"98","author":"FB Dickerson","year":"1998","unstructured":"Dickerson FB, Ringel NB, Parente F. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand. 1998;98(2):124\u20137.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"5929_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132.x","volume":"108","author":"G Reine","year":"2003","unstructured":"Reine G, Lan\u00e7on C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand. 2003;108(4):297\u2013303.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"5929_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/070674370404900503","volume":"49","author":"L De Haan","year":"2004","unstructured":"De Haan L, Lavalaye J, Van Bruggen M, Van Nimwegen L, Booij J, Van Amelsvoort T, et al. Subjective experience and dopamine D 2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry. 2004;49(5):290\u20136.","journal-title":"Can J Psychiatry"},{"issue":"suppl 1","key":"5929_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4088\/JCP.13049su1c.01","volume":"75","author":"B Kirkpatrick","year":"2014","unstructured":"Kirkpatrick B. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression. J Clin Psychiatry. 2014;75(suppl 1):3\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"5929_CR42","first-page":"845","volume":"24","author":"LA Schrimpf","year":"2018","unstructured":"Schrimpf LA, Aggarwal A, Lauriello J, Psychosis CONTIN. Lifelong Learn Neurol. 2018;24(3):845\u201360.","journal-title":"Lifelong Learn Neurol"},{"issue":"5","key":"5929_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1034\/j.1600-0447.2001.00254.x","volume":"103","author":"PB Fitzgerald","year":"2001","unstructured":"Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand. 2001;103(5):387\u201392.","journal-title":"Acta Psychiatr Scand"},{"issue":"13","key":"5929_CR44","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40265-017-0789-y","volume":"77","author":"SRT Veerman","year":"2017","unstructured":"Veerman SRT, Schulte PFJ, De Haan L. Treatment for negative symptoms in Schizophrenia: a Comprehensive Review. Drugs. 2017;77(13):1423\u201359.","journal-title":"Drugs"},{"issue":"S1","key":"5929_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1475-6773.13905","volume":"57","author":"J Zhen-Duan","year":"2022","unstructured":"Zhen-Duan J, Chary A, NeMoyer A, Fukuda M, Markle SL, Hoyos M, et al. Key stakeholder perspectives on the use of research about supported employment for racially and ethnically diverse patients with mental illness in the United States. Health Serv Res. 2022;57(S1):95\u2013104.","journal-title":"Health Serv Res"},{"key":"5929_CR46","doi-asserted-by":"crossref","unstructured":"Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bouso\u00f1o M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007; 9(2).","DOI":"10.31887\/DCNS.2007.9.2\/jbobes"},{"issue":"7","key":"5929_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.comppsych.2012.03.003","volume":"53","author":"X Guo","year":"2012","unstructured":"Guo X, Zhang Z, Zhai J, Fang M, Hu M, Wu R, et al. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Compr Psychiatry. 2012;53(7):1006\u201312.","journal-title":"Compr Psychiatry"},{"issue":"10","key":"5929_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of Placebo-controlled antipsychotic drug trials in Acute Schizophrenia: systematic review, bayesian Meta-analysis, and Meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927\u201342.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5929_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0924-977X(01)00128-6","volume":"12","author":"M Ritsner","year":"2002","unstructured":"Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol. 2002;12(1):31\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"15\u201316","key":"5929_CR50","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/j.1365-2702.2010.03659.x","volume":"20","author":"YL Chiang","year":"2011","unstructured":"Chiang YL, Klainin-Yobas P, Ignacio J, Chng CML. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs. 2011;20(15\u201316):2172\u201382.","journal-title":"J Clin Nurs"},{"issue":"1","key":"5929_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","volume":"18","author":"E Achtyes","year":"2018","unstructured":"Achtyes E, Simmons A, Skabeev A, Levy N, Jiang Y, Marcy P, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia. BMC Psychiatry. 2018;18(1):292.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"5929_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/1574886314666190301152734","volume":"14","author":"J Read","year":"2019","unstructured":"Read J, Williams J. Positive and negative effects of antipsychotic medication: an International Online Survey of 832 recipients. Curr Drug Saf. 2019;14(3):173\u201381.","journal-title":"Curr Drug Saf"},{"issue":"4","key":"5929_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.comppsych.2005.08.006","volume":"47","author":"I Hasson-Ohayon","year":"2006","unstructured":"Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M. Insight into psychosis and quality of life. Compr Psychiatry. 2006;47(4):265\u20139.","journal-title":"Compr Psychiatry"},{"key":"5929_CR54","doi-asserted-by":"crossref","unstructured":"Hasan A, Falkai P, Lehmann I, Gaebel W. Schizophrenia. Deutsches \u00c4rzteblatt international 2020.","DOI":"10.3238\/arztebl.2020.0412"},{"issue":"2","key":"5929_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/08039488.2020.1811374","volume":"75","author":"M Verma","year":"2021","unstructured":"Verma M, Grover S, Chakrabarti S. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. Nord J Psychiatry. 2021;75(2):135\u201344.","journal-title":"Nord J Psychiatry"},{"issue":"2\u20133","key":"5929_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psychres.2004.10.009","volume":"133","author":"SA Strejilevich","year":"2005","unstructured":"Strejilevich SA, Palatnik A, Avila R, Bustin J, Cassone J, Figueroa S, et al. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res. 2005;133(2\u20133):277\u201380.","journal-title":"Psychiatry Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:02:56Z","timestamp":1719907376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5929"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05929-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of Beijing Anding Hospital, Capital Medical University. Written informed consent to participate in this study was provided by participants or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Yi-lang Tang receives research funding from the U.S. Department of Veterans Administration for a medication clinical trial for alcohol use disorder.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"484"}}